Cargando…
Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients
BACKGROUND: In this report we present the results of the retrospective (survival and classification) analyses of possible prognostic factors prolonging survival in epithelial ovarian cancer brain metastases patients after stereotactic radiotherapy. We focus on a wide range of available predictors to...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147185/ https://www.ncbi.nlm.nih.gov/pubmed/25298327 http://dx.doi.org/10.1186/s13048-014-0079-1 |
_version_ | 1782332393565192192 |
---|---|
author | Celejewska, Agata Tukiendorf, Andrzej Miszczyk, Leszek Składowski, Krzysztof Wydmański, Jerzy Trela-Janus, Krystyna |
author_facet | Celejewska, Agata Tukiendorf, Andrzej Miszczyk, Leszek Składowski, Krzysztof Wydmański, Jerzy Trela-Janus, Krystyna |
author_sort | Celejewska, Agata |
collection | PubMed |
description | BACKGROUND: In this report we present the results of the retrospective (survival and classification) analyses of possible prognostic factors prolonging survival in epithelial ovarian cancer brain metastases patients after stereotactic radiotherapy. We focus on a wide range of available predictors to establish survival in patients with a good health status and no more than three lesions. METHODS: Two parallel statistical methods in survival analysis were used: classical and Bayesian methods to verify statistical results. To display the predicted and posterior survivals, classification trees were built. RESULTS: From the initial set of prognostic factors, only four were established as statistically significant in multivariate regression. They were: survival to metastases to brain after epithelial ovarian cancer diagnosis, number of metastases at diagnosis, central nervous system radiotherapy prior to stereotactic radiotherapy, and interval to stereotactic radiotherapy after metastases diagnosis. CONCLUSIONS: When considering evidence-based standards of treatment of patients suffering from epithelial ovarian cancer brain metastases, the established clinical factors are suggested to be prognostic. |
format | Online Article Text |
id | pubmed-4147185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41471852014-08-29 Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients Celejewska, Agata Tukiendorf, Andrzej Miszczyk, Leszek Składowski, Krzysztof Wydmański, Jerzy Trela-Janus, Krystyna J Ovarian Res Research BACKGROUND: In this report we present the results of the retrospective (survival and classification) analyses of possible prognostic factors prolonging survival in epithelial ovarian cancer brain metastases patients after stereotactic radiotherapy. We focus on a wide range of available predictors to establish survival in patients with a good health status and no more than three lesions. METHODS: Two parallel statistical methods in survival analysis were used: classical and Bayesian methods to verify statistical results. To display the predicted and posterior survivals, classification trees were built. RESULTS: From the initial set of prognostic factors, only four were established as statistically significant in multivariate regression. They were: survival to metastases to brain after epithelial ovarian cancer diagnosis, number of metastases at diagnosis, central nervous system radiotherapy prior to stereotactic radiotherapy, and interval to stereotactic radiotherapy after metastases diagnosis. CONCLUSIONS: When considering evidence-based standards of treatment of patients suffering from epithelial ovarian cancer brain metastases, the established clinical factors are suggested to be prognostic. BioMed Central 2014-08-15 /pmc/articles/PMC4147185/ /pubmed/25298327 http://dx.doi.org/10.1186/s13048-014-0079-1 Text en © Celejewska et al.; licensee BioMed Central Ltd 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Celejewska, Agata Tukiendorf, Andrzej Miszczyk, Leszek Składowski, Krzysztof Wydmański, Jerzy Trela-Janus, Krystyna Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients |
title | Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients |
title_full | Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients |
title_fullStr | Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients |
title_full_unstemmed | Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients |
title_short | Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients |
title_sort | stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147185/ https://www.ncbi.nlm.nih.gov/pubmed/25298327 http://dx.doi.org/10.1186/s13048-014-0079-1 |
work_keys_str_mv | AT celejewskaagata stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients AT tukiendorfandrzej stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients AT miszczykleszek stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients AT składowskikrzysztof stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients AT wydmanskijerzy stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients AT trelajanuskrystyna stereotacticradiotherapyinepithelialovariancancerbrainmetastasespatients |